unusu
atyp
pneumonia
origin
foshan
guangdong
provinc
mainland
china
novemb
travel
wide
swiftli
lethal
recent
new
diseas
far
near
end
june
total
case
identifi
countri
area
result
death
previous
unknown
diseas
name
sever
acut
respiratori
syndrom
sar
world
health
organ
novel
coronaviru
sarscov
identifi
caus
agent
coronavirus
famili
envelop
singl
positivestrand
rna
virus
caus
diseas
human
anim
coronavirus
known
affect
human
caus
common
cold
determin
complet
genom
sequenc
sarscov
identifi
caus
new
diseas
bioinformat
analys
sequenc
comparison
show
sarscov
close
relat
previous
character
coronavirus
demonstr
approxim
ident
known
coronavirus
sarscov
nucleotid
length
least
open
read
frame
encod
replicas
structur
protein
includ
spike
envelop
membran
nucleocapsid
sever
protein
unknown
function
nucleocapsid
protein
one
major
structur
protein
viru
previou
research
show
varieti
function
includ
particip
transcript
replic
viral
rna
interfer
cell
cycl
process
host
cell
moreov
mani
coronavirus
nucleocapsid
protein
high
immunogen
activ
abundantli
overexpress
infect
factor
suggest
nucleocapsid
protein
may
potenti
sourc
diagnost
antigen
detect
sar
infect
mani
diagnost
method
develop
base
nucleocapsid
protein
order
develop
recombin
protein
use
coat
antigen
enzymeconjug
antigen
enzymelink
immunosorb
assay
detect
antibodi
sarscov
use
express
purif
partial
nucleocapsid
protein
sarsassoci
coronaviru
doubleantigen
sandwich
assay
develop
use
test
clinic
serum
sampl
result
present
serum
sampl
collect
follow
group
individu
hospit
patient
categor
confirm
suspect
sar
case
convalesc
individu
gener
hospit
chines
peopl
liber
armi
pla
armi
hospit
pla
armi
hospit
pla
sinojapan
friendship
hospit
yongdinglu
hospit
sar
outbreak
beij
china
april
june
patient
diseas
gener
hospit
chines
pla
healthcar
worker
close
contact
sarsinfect
patient
xiaotangshan
hospit
receiv
sar
case
total
rna
sarscov
kindli
provid
zhejiang
provinc
branch
center
diseas
control
prevent
thermoscript
rtpcr
system
invitrogen
san
diego
ca
usa
use
obtain
nucleocapsid
gene
accord
manufactur
instruct
forward
primer
underlin
sequenc
repres
bamhi
site
revers
primer
underlin
sequenc
repres
ecori
site
design
amplifi
gene
anoth
revers
primer
sequenc
bold
ital
type
ad
also
design
base
add
four
lysin
ctermin
recombin
protein
amplifi
nucleocapsid
gene
product
purifi
use
wizard
pcr
purif
kit
promega
madison
wi
usa
follow
digest
ecori
bamhi
takara
tokyo
japan
product
amplifi
two
pair
primer
name
n
respect
express
nucleocapsid
recombin
protein
digest
dna
fragment
subsequ
clone
pgex
gst
fusion
vector
amersham
pharmacia
biotech
piscataway
nj
usa
bamhi
ecori
site
recombin
clone
identifi
pcr
confirm
sequenc
right
recombin
plasmid
transform
novagen
madison
wi
usa
express
nucleocapsid
protein
freshli
isol
coloni
chosen
incub
overnight
liquid
medium
contain
ampicillin
overnight
cultur
dilut
fresh
medium
incub
optic
densiti
od
cultur
measur
nm
reach
mm
isopropylbdthiogalactopyranosid
ad
cultur
growth
continu
next
h
purif
fusion
protein
perform
use
glutathion
sepharos
amersham
pharmacia
biotech
accord
manufactur
specif
protein
concentr
determin
accord
lowri
method
purifi
recombin
protein
protein
extract
induc
recombin
cell
resuspend
sodium
dodecyl
sulfat
sd
mm
ph
boil
min
subject
electrophoresi
sdspolyacrylamid
gel
gel
stain
coomassieblu
amersham
pharmacia
biotech
western
blot
protein
transfer
polyvinyliden
diflourid
membran
electrotransf
transfer
polyvinyliden
diflourid
membran
sigma
st
loui
mo
usa
block
block
buffer
phosphatebuff
salin
pb
supplement
dri
skim
milk
pbsm
min
room
temperatur
block
membran
incub
antiserum
mous
vaccin
inactiv
sar
coronaviru
dilut
pbsm
h
neg
control
also
set
incub
serum
healthi
individu
bound
antibodi
detect
use
horseradish
peroxidas
hrp
conjug
antigoat
igg
sigma
peroxidas
activ
reveal
use
ecl
kit
amersham
pharmacia
biotech
hrpconjug
antigen
prepar
accord
procedur
develop
nakan
kawaoi
modifi
wilson
nakan
remov
unconjug
hrp
conjug
solut
subject
sephadex
column
amersham
pharmacia
biotech
bind
capac
ie
mole
rate
hrp
antigen
hrpconjug
antigen
analyz
use
calcul
valu
valenc
hrpconjug
antigen
determin
checkerboard
titrat
optim
concentr
antigen
conjug
determin
use
checkerboard
titrat
well
microtit
plastic
plate
nunc
roskild
denmark
coat
ng
glutathion
sulfotransferasen
protein
mm
carbon
buffer
ph
overnight
incub
well
wash
three
time
pb
contain
block
bovin
serum
albumin
dissolv
moll
pb
ph
h
well
wash
three
time
pb
contain
dri
room
temperatur
h
sampl
detect
sera
hrpconjug
antigen
ad
well
neg
posit
control
includ
plate
incub
min
follow
three
round
wash
tmb
sigma
substrat
solut
ad
plate
incub
min
color
reaction
stop
addit
sulfur
acid
determin
use
micropl
reader
thermo
labsystem
helsinki
finland
realtim
rt
pcr
detect
sarscov
perform
describ
previous
rtpcr
perform
volum
final
mixtur
contain
rna
mm
ph
mm
kcl
mm
nm
fluoresc
probe
quencher
probe
primer
datp
dctp
dgtp
dutp
u
avian
myeloblastosi
viru
revers
transcriptas
promega
u
taq
dna
polymeras
promega
thermal
cycl
condit
min
min
cycl
use
icycl
iq
realtim
pcr
detect
system
biorad
realtim
detect
perform
anneal
temperatur
cycl
primer
design
amplifi
second
half
nucleocapsid
gene
nt
expect
size
bp
analyz
agaros
gel
electrophoresi
partial
nucleocapsid
gene
product
expect
size
obtain
purifi
pcr
product
digest
bamhi
ecori
clone
order
obtain
glutathionestransferas
gst
fusion
protein
plasmid
transform
escherichia
coli
express
gstn
fusion
protein
recombin
clone
identifi
pcr
plasmid
correct
size
confirm
sequenc
nucleotid
sequenc
deduc
amino
acid
sequenc
avail
genbank
access
number
recombin
nucleocapsid
protein
success
express
e
coli
fusion
protein
gstn
protein
extract
induc
recombin
cell
purifi
recombin
nucleocapsid
protein
analyz
use
sdspolyacrylamid
gel
coomassi
blue
stain
express
nucleocapsid
fusion
protein
approxim
molecular
mass
kda
accord
expect
size
fusion
protein
highli
express
e
coli
amount
fusion
protein
total
protein
cell
lysat
fusion
protein
purifi
glutathionesepharos
puriti
recombin
nucleocapsid
protein
reach
follow
western
blot
analysi
antiserum
mous
vaccin
inactiv
sarscov
purifi
fusion
protein
react
strongli
specif
antiserum
nonspecif
band
shown
neg
control
indic
four
lysin
ctermin
affect
antigen
prepar
hrpantigen
conjug
high
activ
sandwich
elisa
gstn
coupl
hrp
hrpantigen
conjug
high
activ
chosen
activ
conjug
determin
mole
ratio
hrp
antigen
valenc
conjug
calcul
mole
ratio
gstnhrp
conjug
conjug
p
valu
calcul
use
student
ttest
show
bind
capac
conjug
better
valenc
gstnhrp
determin
checkerboard
titrat
respect
sinc
result
indic
conjug
better
sandwich
elisa
conjug
use
elisa
hrp
react
primari
amin
antigen
number
primari
amin
affect
effici
order
increas
bind
capac
antigen
hrp
antigen
design
four
lysin
ctermin
gstn
four
extra
lysin
increas
number
primari
amin
show
higher
bind
capac
gstn
reaction
hrp
optimum
concentr
coat
antigen
dilut
fold
hrpconjug
antigen
elisa
determin
checkerboard
serialdilut
analysi
posit
neg
serum
sampl
use
analysi
combin
gave
highest
pn
ratio
od
posit
controlod
neg
control
determin
optim
result
show
ngwell
antigen
combin
dilut
conjug
gave
highest
pn
ratio
determin
optim
od
cutoff
valu
elisa
assay
allow
discrimin
sampl
posit
neg
sar
human
sera
healthi
individu
test
elisa
data
shown
mean
od
x
standard
deviat
sd
valu
calcul
respect
cutoff
valu
acquir
calcul
investig
specif
sensit
elisa
assay
panel
set
nation
institut
control
pharmaceut
biolog
product
beij
china
employ
includ
posit
sera
neg
sera
serial
dilut
serum
sensit
control
test
posit
maximum
dilut
assay
immunofluoresc
indirect
elisa
viru
lysat
antigen
posit
sera
produc
od
greater
cutoff
point
neg
sera
gave
od
moreov
sensit
control
serum
dilut
gave
od
result
prove
elisa
sensit
specif
method
detect
sarscov
antibodi
repeat
sandwich
elisa
intra
interassay
precis
assess
use
posit
qualitycontrol
sera
coeffici
variat
rang
intraassay
precis
interassay
precis
indic
elisa
specif
sensit
repeat
method
investig
perform
sandwich
elisa
sampl
sarsconfirm
suspect
patient
convalesc
individu
patient
diseas
healthcar
worker
analyz
result
summar
tabl
singl
posit
result
found
among
patient
diseas
detect
od
analysi
result
obtain
clinic
sampl
reveal
good
specif
elisa
although
percentag
sampl
test
posit
elisa
may
due
inclus
sampl
patient
misdiagnos
sar
sar
outbreak
misdiagnosi
occur
frequent
effort
prevent
spread
diseas
among
specimen
patient
suspect
sar
may
collect
patient
actual
infect
unfortun
possibl
us
follow
patient
sampl
collect
variou
time
outbreak
thu
sure
mani
patient
group
eventu
exclud
howev
eight
case
knew
exclud
place
separ
group
elisa
produc
neg
result
patient
sarsconfirm
case
detect
elisa
may
due
low
antibodi
titer
elisaneg
patient
world
health
organ
report
test
detect
sarscov
might
posit
earli
day
onset
ill
often
day
sometim
posit
result
achiev
day
ill
onset
case
test
sampl
collect
patient
ill
less
day
weakli
posit
wherea
sampl
patient
ill
day
posit
number
case
small
statist
analysi
result
certain
extent
accord
previou
report
find
convalesc
individu
test
posit
sarscov
antibodi
suggest
sar
antibodi
may
disappear
individu
could
later
becom
reinfect
evalu
effect
sandwich
elisa
confirm
case
also
test
realtim
pcr
result
accord
stage
ill
sampl
obtain
shown
tabl
sampl
patient
ill
less
day
percentag
detect
sandwich
elisa
lower
detect
realtim
pcr
five
sera
collect
day
ill
onset
elisa
detect
five
sampl
realtim
pcr
detect
two
sera
collect
middl
stage
ill
ie
day
ill
onset
two
assay
gave
similar
result
compar
realtim
rtpcr
sandwich
elisa
less
effect
detect
sarscov
earli
stage
ill
effect
detect
antibodi
patient
ill
day
result
indic
combin
rtpcr
elisa
would
effect
mean
detect
sar
pathogen
trial
percentag
case
detect
realtim
pcr
unsatisfactori
even
sampl
obtain
earli
stage
ill
may
due
ineffici
isol
nucleic
acid
nonstandard
sampl
possibl
result
reduc
level
rna
primari
trial
protein
microarray
data
shown
nucleocapsid
protein
especi
second
half
locat
ctermin
protein
show
strong
antigen
use
polypeptid
antigen
develop
doubleantigen
sandwich
elisa
detect
antibodi
sarscov
serum
base
find
doubleantigen
sandwich
elisa
employ
recombin
n
protein
serodiagnost
antigen
use
enzymeconjug
antigen
instead
enzymeconjug
secondari
antibodi
provid
safe
specif
sensit
mean
detect
confirm
sar
infect
